To mimic the effect of mTORC1 activity changes in depression in vivo, HT-22 and BV2 were treated with mTORC1 inhibitor rapamycin (200 nM), and then the changes of Pdcd4 and BDNF expression were measured by western blot and ELISA. This evidence concerns the gene BDNF and depressive symptom measurement.